Arsanis, Inc.
Arsanis, Inc. is listed today as X4 Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
5 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2025 | $85 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| May 2023 | $65 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Jul 2022 | $56 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Nov 2017 | $20 M | No. 5 | $10 to $50 million | equity | SEC | |
| Apr 2017 | $46 M | No. 4 | $10 to $50 million | equity | SEC | |
| Apr 2016 | $15 M | No. 3 | $10 to $50 million | equity, debt | SEC | |
| Jul 2013 | $20 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jan 2011 | $10 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company X4 Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: License and other revenue $28.59 million (81%).
Annual report (SEC XBRL) · Dec 2025
Arsanis, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2025).
SEC Form D · Aug 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2025
Products and services#
No products or services of Arsanis, Inc. are on record.
Investors#
28 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Alphabet Inc. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Anna-Maria & Stephen Kellen Foundation, Inc. | Company | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Bill & Melinda Gates Foundation | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| EMBL Technology Fund II GmbH & Co. KG | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| EMBL Ventures Verwaltungs GmbH | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| GV 2016 GP, L.L.C. | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| GV 2016 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| GV 2016, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| NeoMed Innovation V L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| NeoMed Innovation V Ltd | Company | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| NeoMed Management (Jersey) Ltd | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| OrbiMed Capital GP IV LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Polaris Venture Management Co. V, L.L.C. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Polaris Venture Partners Entrepreneurs' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Polaris Venture Partners Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Polaris Venture Partners Special Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Polaris Venture Partners V, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Section 32 Fund 1, LP | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Section 32 GP 1, LLC | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| SV Life Sciences Fund VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| SV Life Sciences Fund VI Strategic Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| SV Life Sciences Fund V LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| SV Life Sciences Fund V Strategic Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Svlsf VI, LLC | Other | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Svlsf V, LLC | Other | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Tillman U. Gerngross | Person | not stated | not stated | Held Series D preferred stock, 10% owner, director (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 18 investors.
Largest shareholders today
Institutions holding X4 Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- Morgan Stanley$32 M10.77%
- Empery Asset Management, LP$28 M9.52%
- Bain Capital Life Sciences Investors, LLC$23 M7.80%
- Venrock Adviser, LLC$22 M7.49%
- Saturn V Capital Management LP$21 M7.21%
- Perceptive Advisors LLC$21 M7.20%
- BlackRock, Inc.$17 M5.73%
- FMR LLC$16 M5.38%
- Deep Track Capital, LP$13 M4.41%
- Kalehua Capital Management LLC$11 M3.65%
- Vanguard Capital Management LLC$10 M3.48%
- Rosalind Advisors, Inc.$9 M3.15%
- Trails Edge Capital Partners, LP$7 M2.52%
- Nantahala Capital Management, LLC$7 M2.40%
- Blackstone Inc.$7 M2.38%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adam Craig | Executive officer | Aug 2025 |
| Christophe Arbet-Engels | Executive officer | Aug 2025 |
| David Kirske | Executive officer | Aug 2025 |
| John Volpone | Executive officer | Aug 2025 |
| Mark Baldry | Executive officer | Aug 2025 |
| Mary DiBiase | Executive officer | Aug 2025 |
| Adam Mostafa | Executive officer | Jun 2023 |
| Arthur Taveras | Executive officer | Jun 2023 |
| Murray Stewart | Executive officer | Jun 2023 |
| Paula Ragan | Executive officer | Jun 2023 |
| Adam S. Mostafa | Chief Financial Officer and Treasurer | Jul 2022 |
| Arthur S. Taveras | Chief Scientific Officer | Jul 2022 |
| Derek S. Meisner | Chief Legal Officer and Corporate Secretary | Jul 2022 |
| Diego S. Cadavid | Chief Medical Officer | Jul 2022 |
| Mary S. DiBiase | Chief Operating Officer | Jul 2022 |
| Chris U. Stevens | Executive officer | Dec 2017 |
| David U. Mantus | Executive officer | Dec 2017 |
| Eszter U. Nagy | Executive officer | Dec 2017 |
| Michael Gray | Executive officer | Dec 2017 |
| Rene Russo | Executive officer | Dec 2017 |
| Tillman U. Gerngross | Executive officer | May 2017 |
| Eszter Nagy | Executive officer | Apr 2016 |
| Tillman Gerngross | Executive officer | Apr 2016 |
| Eszter U Nagy | Executive officer | Jun 2015 |
| Tillman U Gerngross | Executive officer | Jun 2015 |
| Errik B Anderson | Executive officer | Aug 2014 |
| Eszter B Nagy | Executive officer | Aug 2014 |
| Errik B. Anderson | Executive officer | Feb 2011 |
| Robert L. Birnbaum | Executive officer | Feb 2011 |
| Adam Craig | Director | Aug 2025 |
| Francoise J. De Craecker | Director | Aug 2025 |
| Gary J. Bridger | Director | Aug 2025 |
| Michael S. Wyzga | Director | Aug 2025 |
| Murray W. Stewart | Director | Aug 2025 |
| Alison Lawton | Director | Jun 2023 |
| David McGirr | Director | Jun 2023 |
| Francoise de Craecker | Director | Jun 2023 |
| Gary Bridger | Director | Jun 2023 |
| Michael Wyzga | Director | Jun 2023 |
| Murray Stewart | Director | Jun 2023 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.